Drug intelligence / Profile preview

UQSC2

Development stage: Phase 1
Lead developer: The University of Queensland
Modality: Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

UQSC2 is a prophylactic protein subunit vaccine developed as an immunostimulant for the prevention of COVID-19 and Severe Acute Respiratory Syndrome. It was initially developed by The University of Queensland, with support from the Coalition for Epidemic Preparedness Innovations. The vaccine is designed to stimulate the immune system to generate protective immunity against SARS-CoV-2, the virus responsible for COVID-19. As of May 2025, its highest global R&D status is Phase 1 clinical trials, where it has been evaluated in healthy adults aged 18–50 years for safety and immunogenicity[1].

Targets

SARS-CoV-2 spike-specific T cell receptorTLR3 (Toll-like receptor 3)BCR (Immunoglobulin G B Cell Receptor)

Beyond the preview

Go deeper on UQSC2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UQSC2.

Explore the full profile